Navigation Links
OncoGenex increases economic interest in lead cancer drug OGX-011
Date:7/3/2008

VANCOUVER, July 3 /PRNewswire/ - OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the companies have amended their agreement and OncoGenex has elected to independently develop its lead cancer drug OGX-011. Under the amended agreement, OncoGenex is solely responsible for all future development activities, costs and partnering decisions related to OGX-011. Isis will no longer be responsible for funding 35% of development costs, will receive single digit royalties on future revenues of OGX-011, and will receive a portion of license fees and milestone payments received by OncoGenex from any future partner. There were no upfront payments associated with this amended agreement.

"This amendment allows us to increase our economic interest in OGX-011 as we advance the development of OGX-011 while also increasing our flexibility to further develop this product candidate," said Scott Cormack, President and CEO of OncoGenex. "In addition, we believe this new arrangement facilitates future partnering discussions since potential development and commercialization partners need only deal with one party."

"This amended agreement with OncoGenex is consistent with our strategy to remain focused on discovering and developing drugs and licensing prior to large Phase 3 trials. This has enabled us to continue to benefit from the successes of antisense drugs through a growing annuity of licensing fees, milestones and royalty payments with many focused partners," said B. Lynne Parshall, COO and CFO of Isis. "We believe that clinical results to date have established OGX-011 as one of many promising antisense drugs and OncoGenex is now ideally situated to lead the final stages of development of OGX-011 whi
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 GEA Niro Soavi the leader ... homogenizer, the PandaPLUS 2000, which is ideal for new ... cell disruption . This compact laboratory homogenizer is ... liquid food, food additives and ingredients as well as ...
(Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
(Date:1/22/2015)... January 22, 2015 Dr. Greg Leyer of ... annual Scripps Natural Supplements Pre-Conference seminar on probiotics in San ... an annual continuing education conference for health care professionals. This ... the topic of probiotics in health. Dr. Leyer spoke about ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... HAYWARD, Calif., March 18 Kosan Biosciences,Incorporated (Nasdaq: ... of Directors has,appointed Helen S. Kim as Chief ... January 2008 as Senior Vice President and Chief,Business ... Peter Davis, PhD., Kosan,s Chairman of the ...
... 18 Three biotech CEOs and,the president of ... honored,today by the Greater Baltimore Committee as winners ... of the 2008 Greater Baltimore Region Bioscience Awards ... Timothy E. Askew, President & CEO, CSA,Medical, Inc. ...
... Successfully Hit Primary End Point of Preventing ... Superiority over the Market Leader, VANCOUVER, ... ANPI , TSX: ANP), a global ... that the clinical data from its 960,patient ...
Cached Biology Technology:Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 2Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 3Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer 4Three CEOs and University President Named Winners of Greater Baltimore Committee's 2008 Baltimore Region Bioscience Awards 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 3960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 4960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 5960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 6960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 7
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)...  HITLAB SM announced today its completion of a ... to current U.S. Food and Drug Administration (FDA) regulations. ... and smart phone application trials utilizing the highest principles ... is determined to improve global healthcare access, quality, and ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... -- The key to understanding how future hurricanes and sea ... forests lurks below the surface, according to a new model ... mangroves that line the coasts lie hardwood hammocks that are ... University of Miami (UM) Ecologist Donald L. DeAngelis, who is ...
... dinner on R.V. Calypso while anchored on the lee side ... that he suspected humans were having a negative impact on ... the lush coral reefs of the Caribbean and Sinai Peninsulafound ... But Cousteau was right. During the following three-plus decades, Dustan, ...
... Location matters for birds on the hunt for caterpillars, according ... that chickadees and others zero in on the type of ... Unfortunately for caterpillars, munching on tree leaves that are ... becoming food. Study results, published online this week in ...
Cached Biology News:Living on the edge: An innovative model of mangrove-hammock boundaries in Florida 2Detecting detrimental change in coral reefs 2Detecting detrimental change in coral reefs 3For the birds 2